BlueRock Therapeutics Sets Up HQ in Cambridge, Expands Executive Team
BlueRock Therapeutics established its corporate headquarters in Cambridge, MA and has appointed two additional senior executive staffers. Source: BioSpace
BlueRock Therapeutics established its corporate headquarters in Cambridge, MA and has appointed two additional senior executive staffers. Source: BioSpace
BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation. Source: BioSpace
Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16. Source: BioSpace
The former Biogen CEO is making waves at his new venture, Vir Biotechnology. Source: BioSpace
Ablynx announced the price of its U.S. IPO at $17.50. Source: BioSpace
In addition to the layoffs, the company is also looking to divest its Infectious Disease Business. Source: BioSpace
Biogen released its third-quarter financials yesterday, showing total revenues of $3.1B for the quarter, a 4 percent gain compared to the same period the previous year. Source: BioSpace
Corbus' stock popped on the release of topline results from a midstage study involving its lead (and only) clinical drug, anabasum. Source: BioSpace
Incyte has been at the forefront of the IDO race with its candidate epacadostat. Source: BioSpace
The drug developed by Nogra always seemed like a longshot, but Celgene management talked it up over the years as it advanced. Source: BioSpace